Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Transcriptomic analysis of mRNA expression and alternative splicing during mouse sex determination.

Zhao L, Wang C, Lehman ML, He M, An J, Svingen T, Spiller CM, Ng ET, Nelson CC, Koopman P.

Mol Cell Endocrinol. 2018 Jul 24. pii: S0303-7207(18)30234-X. doi: 10.1016/j.mce.2018.07.010. [Epub ahead of print]

PMID:
30053582
2.

Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool.

Wang C, Moya L, Clements JA, Nelson CC, Batra J.

Biol Chem. 2018 Jul 27. pii: /j/bchm.ahead-of-print/hsz-2017-0322/hsz-2017-0322.xml. doi: 10.1515/hsz-2017-0322. [Epub ahead of print]

PMID:
30052511
3.

Racial/Ethnic Differences in the Effectiveness of a Multisector Childhood Obesity Prevention Intervention.

Nelson CC, Colchamiro R, Perkins M, Taveras EM, Leung-Strle P, Kwass J, Woo Baidal JA.

Am J Public Health. 2018 Sep;108(9):1200-1206. doi: 10.2105/AJPH.2018.304511. Epub 2018 Jul 19.

PMID:
30024810
4.

Early Return to Work has Benefits for Relief of Back Pain and Functional Recovery after Controlling for Multiple Confounds.

Shaw WS, Nelson CC, Woiszwillo MJ, Gaines B, Peters SE.

J Occup Environ Med. 2018 Jun 21. doi: 10.1097/JOM.0000000000001380. [Epub ahead of print]

PMID:
29933319
5.

Identification of Gibberellic Acid Derivatives That Deregulate Cholesterol Metabolism in Prostate Cancer Cells.

Egbewande FA, Sadowski MC, Levrier C, Tousignant KD, White JM, Coster MJ, Nelson CC, Davis RA.

J Nat Prod. 2018 Apr 27;81(4):838-845. doi: 10.1021/acs.jnatprod.7b00929. Epub 2018 Feb 23.

PMID:
29474071
6.

Lymphedema-Distichiasis Syndrome in a Male Patient Followed for 16 Years.

Grisolia ABD, Nelson CC.

Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):e63-e65. doi: 10.1097/IOP.0000000000001037.

PMID:
29342028
7.

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.

Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S; Australian Prostate Cancer BioResource, Lehman ML, Nelson CC, Clements JA, Batra J.

Sci Rep. 2017 Dec 4;7(1):16862. doi: 10.1038/s41598-017-16700-y.

8.

Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.

Soekmadji C, Rockstroh A, Ramm GA, Nelson CC, Russell PJ.

Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201600427.

PMID:
29105980
9.

Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours.

Evans JC, Malhotra M, Sweeney K, Darcy R, Nelson CC, Hollier BG, O'Driscoll CM.

Int J Pharm. 2017 Oct 30;532(1):511-518. doi: 10.1016/j.ijpharm.2017.09.013. Epub 2017 Sep 13.

PMID:
28916296
10.

Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.

Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM; Australian Prostate Cancer Collaboration BioResource, Hill MM, Nelson CC.

Oncotarget. 2016 Aug 8;8(32):52237-52255. doi: 10.18632/oncotarget.11111. eCollection 2017 Aug 8.

11.

Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.

Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29. Review.

PMID:
28856701
12.

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.

Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC.

Cell Cycle. 2018;17(5):652-668. doi: 10.1080/15384101.2017.1356512.

13.

Clinical effectiveness of the massachusetts childhood obesity research demonstration initiative among low-income children.

Taveras EM, Perkins M, Anand S, Woo Baidal JA, Nelson CC, Kamdar N, Kwass JA, Gortmaker SL, Barrett JL, Davison KK, Land T.

Obesity (Silver Spring). 2017 Jul;25(7):1159-1166. doi: 10.1002/oby.21866.

14.

Childhood obesity prevention in the women, infants, and children program: Outcomes of the MA-CORD study.

Woo Baidal JA, Nelson CC, Perkins M, Colchamiro R, Leung-Strle P, Kwass JA, Gortmaker SL, Davison KK, Taveras EM.

Obesity (Silver Spring). 2017 Jul;25(7):1167-1174. doi: 10.1002/oby.21865.

15.

Neonatal Graves' Eye Disease.

Segal KL, Nelson CC.

Ophthalmology. 2017 May;124(5):673. doi: 10.1016/j.ophtha.2016.11.009. No abstract available.

PMID:
28433126
16.

Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.

Seim I, Jeffery PL, Thomas PB, Nelson CC, Chopin LK.

G3 (Bethesda). 2017 Jun 7;7(6):1731-1741. doi: 10.1534/g3.117.039909.

17.

Tangent screen perimetry in the evaluation of visual field defects associated with ptosis and dermatochalasis.

Fuller ML, Briceño CA, Nelson CC, Bradley EA.

PLoS One. 2017 Mar 29;12(3):e0174607. doi: 10.1371/journal.pone.0174607. eCollection 2017.

18.

Insights from engraftable immunodeficient mouse models of hyperinsulinaemia.

Maugham ML, Thomas PB, Crisp GJ, Philp LK, Shah ET, Herington AC, Chen C, Gregory LS, Nelson CC, Seim I, Jeffery PL, Chopin LK.

Sci Rep. 2017 Mar 28;7(1):491. doi: 10.1038/s41598-017-00443-x.

19.

Evaluation of Patients with Facial Palsy and Ophthalmic Sequelae: A 23-Year Retrospective Review.

Joseph SS, Joseph AW, Smith JI, Niziol LM, Musch DC, Nelson CC.

Ophthalmic Epidemiol. 2017 Oct;24(5):341-345. doi: 10.1080/09286586.2017.1294186. Epub 2017 Mar 20.

PMID:
28319442
20.

Key Organizational Characteristics for Integrated Approaches to Protect and Promote Worker Health in Smaller Enterprises.

McLellan DL, Williams JA, Katz JN, Pronk NP, Wagner GR, Cabán-Martinez AJ, Nelson CC, Sorensen G.

J Occup Environ Med. 2017 Mar;59(3):289-294. doi: 10.1097/JOM.0000000000000949.

PMID:
28267100
21.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

22.

Prevalence of Body Dysmorphic Disorder and Surgeon Diagnostic Accuracy in Facial Plastic and Oculoplastic Surgery Clinics.

Joseph AW, Ishii L, Joseph SS, Smith JI, Su P, Bater K, Byrne P, Boahene K, Papel I, Kontis T, Douglas R, Nelson CC, Ishii M.

JAMA Facial Plast Surg. 2017 Jul 1;19(4):269-274. doi: 10.1001/jamafacial.2016.1535.

23.

6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.

Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.

Mol Cancer Ther. 2017 Jan;16(1):3-15. doi: 10.1158/1535-7163.MCT-16-0325. Epub 2016 Oct 19.

24.

FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy.

Lexmond WS, Goettel JA, Lyons JJ, Jacobse J, Deken MM, Lawrence MG, DiMaggio TH, Kotlarz D, Garabedian E, Sackstein P, Nelson CC, Jones N, Stone KD, Candotti F, Rings EH, Thrasher AJ, Milner JD, Snapper SB, Fiebiger E.

J Clin Invest. 2016 Oct 3;126(10):4030-4044. doi: 10.1172/JCI85129. Epub 2016 Sep 19.

25.

Assessment of the Abbreviated National Eye Institute Visual Function Questionnaire (NEI VFQ 9) in blepharoptosis and dermatochalasis.

Briceño CA, Fuller ML, Bradley EA, Nelson CC.

Arq Bras Oftalmol. 2016 Jul-Aug;79(4):226-8. doi: 10.5935/0004-2749.20160065.

26.

Short term ex-vivo expansion of circulating head and neck tumour cells.

Kulasinghe A, Perry C, Warkiani ME, Blick T, Davies A, O'Byrne K, Thompson EW, Nelson CC, Vela I, Punyadeera C.

Oncotarget. 2016 Sep 13;7(37):60101-60109. doi: 10.18632/oncotarget.11159.

27.

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.

PMID:
27270433
28.

Erratum to: Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2016 Jun 3;17(1):424. No abstract available.

29.

Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site.

Frohm ML, Griffith KA, Harms KL, Hayman JA, Fullen DR, Nelson CC, Wong SL, Schwartz JL, Bichakjian CK.

JAMA Dermatol. 2016 Sep 1;152(9):1001-7. doi: 10.1001/jamadermatol.2016.1428.

PMID:
27248515
30.

Validation and Dimensionality of the Integration of Health Protection and Health Promotion Score: Evidence From the PULSE Small Business and VA Medical Center Surveys.

Williams JA, Schult TM, Nelson CC, Cabán-Martinez AJ, Katz JN, Wagner GR, Pronk NP, Sorensen G, McLellan DL.

J Occup Environ Med. 2016 May;58(5):499-504. doi: 10.1097/JOM.0000000000000732.

31.

Bioactive Dihydro-β-agarofuran Sesquiterpenoids from the Australian Rainforest Plant Maytenus bilocularis.

Wibowo M, Levrier C, Sadowski MC, Nelson CC, Wang Q, Holst J, Healy PC, Hofmann A, Davis RA.

J Nat Prod. 2016 May 27;79(5):1445-53. doi: 10.1021/acs.jnatprod.6b00190. Epub 2016 Apr 27.

PMID:
27120798
32.

Repositioning "old" drugs for new causes: identifying new inhibitors of prostate cancer cell migration and invasion.

Shah ET, Upadhyaya A, Philp LK, Tang T, Skalamera D, Gunter J, Nelson CC, Williams ED, Hollier BG.

Clin Exp Metastasis. 2016 Apr;33(4):385-99. doi: 10.1007/s10585-016-9785-y. Epub 2016 Mar 1.

PMID:
26932199
33.

Implementing an Integrated Health Protection/Health Promotion Intervention in the Hospital Setting: Lessons Learned From the Be Well, Work Well Study.

Sorensen G, Nagler EM, Hashimoto D, Dennerlein JT, Theron JV, Stoddard AM, Buxton O, Wallace LM, Kenwood C, Nelson CC, Tamers SL, Grant MP, Wagner G.

J Occup Environ Med. 2016 Feb;58(2):185-94. doi: 10.1097/JOM.0000000000000592.

34.

The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells.

Liberio MS, Sadowski MC, Davis RA, Rockstroh A, Vasireddy R, Lehman ML, Nelson CC.

Oncotarget. 2015 Dec 22;6(41):43944-63. doi: 10.18632/oncotarget.6267.

35.

Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2015 Dec 1;16:1021. doi: 10.1186/s12864-015-2235-4. Erratum in: BMC Genomics. 2016;17:424.

36.

Cytotoxic C20 Diterpenoid Alkaloids from the Australian Endemic Rainforest Plant Anopterus macleayanus.

Levrier C, Sadowski MC, Nelson CC, Davis RA.

J Nat Prod. 2015 Dec 24;78(12):2908-16. doi: 10.1021/acs.jnatprod.5b00509. Epub 2015 Nov 24.

PMID:
26600001
37.

The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer.

Soekmadji C, Nelson CC.

Biomed Res Int. 2015;2015:454837. doi: 10.1155/2015/454837. Epub 2015 Oct 26. Review.

38.

Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer.

Tevz G, McGrath S, Demeter R, Magrini V, Jeet V, Rockstroh A, McPherson S, Lai J, Bartonicek N, An J, Batra J, Dinger ME, Lehman ML, Williams ED, Nelson CC.

Mol Cell Endocrinol. 2016 Jan 15;420:159-68. doi: 10.1016/j.mce.2015.10.011. Epub 2015 Oct 21.

39.

Integrating health promotion and occupational safety and health in manufacturing worksites: Perspectives of leaders in small-to-medium sized businesses.

Nelson CC, Allen JD, McLellan D, Pronk N, Davis KL.

Work. 2015;52(1):169-76. doi: 10.3233/WOR-152038.

PMID:
26410231
40.

Validation of a New Metric for Assessing the Integration of Health Protection and Health Promotion in a Sample of Small- and Medium-Sized Employer Groups.

Williams JA, Nelson CC, Cabán-Martinez AJ, Katz JN, Wagner GR, Pronk NP, Sorensen G, McLellan DL.

J Occup Environ Med. 2015 Sep;57(9):1017-21. doi: 10.1097/JOM.0000000000000521.

41.

Organizational Characteristics Influence Implementation of Worksite Health Protection and Promotion Programs: Evidence From Smaller Businesses.

McLellan DL, Cabán-Martinez AJ, Nelson CC, Pronk NP, Katz JN, Allen JD, Davis KL, Wagner GR, Sorensen G.

J Occup Environ Med. 2015 Sep;57(9):1009-16. doi: 10.1097/JOM.0000000000000517.

42.

GATA3 haploinsufficiency does not block allergic sensitization or atopic disease.

Lawrence MG, Leiding JW, Lyons JJ, Hsu AP, Nelson CC, Jones N, Fitzgerald A, Chien WW, Workman L, Platts-Mills TA, Brewer C, Gafni RI, Stone KD, Milner JD, Holland SM.

J Allergy Clin Immunol. 2016 Feb;137(2):627-629.e2. doi: 10.1016/j.jaci.2015.06.041. Epub 2015 Aug 15. No abstract available.

43.

Supervisors' support for nurses' meal breaks and mental health.

Hurtado DA, Nelson CC, Hashimoto D, Sorensen G.

Workplace Health Saf. 2015 Mar;63(3):107-15. doi: 10.1177/2165079915571354.

PMID:
25994975
44.

The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-β8 in prostate cancer cells.

Mertens-Walker I, Fernandini BC, Maharaj MS, Rockstroh A, Nelson CC, Herington AC, Stephenson SA.

BMC Cancer. 2015 Mar 22;15:164. doi: 10.1186/s12885-015-1164-6.

45.

Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer.

Stuchbery R, Kurganovs NJ, McCoy PJ, Nelson CC, Hayes VM, Corcoran NM, Hovens CM.

Curr Cancer Drug Targets. 2015;15(5):394-405. Review.

PMID:
25882061
46.

Design and Synthesis of a Screening Library Using the Natural Product Scaffold 3-Chloro-4-hydroxyphenylacetic Acid.

Kumar R, Sadowski MC, Levrier C, Nelson CC, Jones AJ, Holleran JP, Avery VM, Healy PC, Davis RA.

J Nat Prod. 2015 Apr 24;78(4):914-8. doi: 10.1021/np500856u. Epub 2015 Mar 24.

47.

RNASeqBrowser: a genome browser for simultaneous visualization of raw strand specific RNAseq reads and UCSC genome browser custom tracks.

An J, Lai J, Wood DL, Sajjanhar A, Wang C, Tevz G, Lehman ML, Nelson CC.

BMC Genomics. 2015 Mar 1;16:145. doi: 10.1186/s12864-015-1346-2.

48.

Public health 101 nanocourse: a condensed educational tool for non-public health professionals.

Ramirez CL, Gajdos ZK, Kreatsoulas C, Afeiche MC, Asgarzadeh M, Nelson CC, Kanjee U, Caban-Martinez AJ.

Am J Public Health. 2015 Mar;105 Suppl 1:S50-4. doi: 10.2105/AJPH.2014.302305.

49.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.

PMID:
25701452
50.

Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.

Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JE, Holst J.

J Pathol. 2015 Jul;236(3):278-89. doi: 10.1002/path.4518. Epub 2015 Apr 7.

Supplemental Content

Loading ...
Support Center